Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients—a description of the DAPACARD study

Background: Diabetes increases the risk for cardiovascular (CV) events. It has recently been shown that the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors leads to a reduction in CV outcomes in patients with type 2 diabetes mellitus (T2DM), including mortality and heart failure hospitaliza...

Descripción completa

Detalles Bibliográficos
Autores principales: Åkerblom, Axel, Oldgren, Jonas, Latva-Rasku, Aino, Johansson, Lars, Lisovskaja, Vera, Karlsson, Cecilia, Oscarsson, Jan, Nuutila, Pirjo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450503/
https://www.ncbi.nlm.nih.gov/pubmed/30618324
http://dx.doi.org/10.1080/03009734.2018.1515281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450503/
https://www.ncbi.nlm.nih.gov/pubmed/30618324
http://dx.doi.org/10.1080/03009734.2018.1515281

Ejemplares similares